Quick Takeaways
- PharmaCyte Biotech, Inc. filed SCHEDULE 13D/A for Q/C TECHNOLOGIES, INC. Common Stock, par value $0.001 per share (QCLS).
- Disclosed ownership: 74%.
- Date of event: 14 Nov 2025.
PharmaCyte Biotech, Inc. - 14 Nov 2025 SCHEDULE 13D/A Report for Q/C TECHNOLOGIES, INC. Common Stock, par value $0.001 per share (QCLS)
- Filing Manager
- PharmaCyte Biotech, Inc.
- Reporting Manager
- PharmaCyte Biotech, Inc.
- Symbol
- QCLS
- Shares outstanding
- 11,453,200 shares
- Disclosed Ownership
- 8,475,368 shares
- Ownership
- 74%
- Form type
- SCHEDULE 13D/A
- Filing time
- 18 Nov 2025, 16:29:55 UTC
- Date of event
- 14 Nov 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"PharmaCyte Biotech, Inc. disclosed 74% ownership in Q/C TECHNOLOGIES, INC. Common Stock, par value $0.001 per share (QCLS) on 14 Nov 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 18 Nov 2025, 16:29.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| PharmaCyte Biotech, Inc. | 74% | 8,475,368 | 0 | 8,475,368 | /s/ Carlos Trujillo | Carlos Trujillo | 0001157075 |